Baxter Reports Strong Q1 2026 Results, Shares Rise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2026
0mins
Source: Yahoo Finance
Baxter International Inc (BAX) shares rose by 6.04% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment following the company's Q1 2026 earnings report.
Baxter reported $2.7 billion in revenue for Q1 2026, exceeding expectations by $80 million, with international sales contributing significantly to this growth. Despite a decline in U.S. sales, the company reaffirmed its full-year outlook, indicating confidence in future performance. The adjusted EPS of $0.36 also beat estimates, showcasing resilience despite challenges in cost management.
The strong international sales growth and positive earnings surprise have bolstered investor confidence, leading to a notable increase in share price. Baxter's reaffirmation of its sales growth outlook further supports a positive trajectory for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 19.390
Low
15.00
Averages
22.13
High
30.00
Current: 19.390
Low
15.00
Averages
22.13
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MediThinQ and Synovis Sign Global Exclusive Agreement
- Global Distribution Agreement: MediThinQ has entered into an exclusive multi-year distribution agreement with Synovis MCA, a subsidiary of Baxter, to promote its 3D surgical visualization platform SHIYA worldwide; while the terms remain undisclosed, this move is expected to significantly enhance SHIYA's accessibility and acceptance in international markets.
- Technological Transformation: SHIYA combines a high-resolution digital exoscope with the proprietary wearable display SCOPEYE, allowing surgeons to operate without traditional eyepieces, thereby enhancing surgical flexibility and team collaboration, which is crucial for modern surgical practices.
- Clinical Validation and Future Applications: SHIYA has been utilized in over 100 procedures globally, with peer-reviewed studies highlighting its potential in microsurgery, particularly in augmented reality and data-assisted surgical techniques, indicating a fundamental shift in surgical methodologies.
- Market Promotion Strategy: The collaboration with Synovis MCA provides the commercial infrastructure necessary for SHIYA's phased rollout across various countries, ensuring compliance with local regulatory requirements, which will accelerate the global adoption of digital surgical visualization technologies.
See More
Investment Opportunities After Dividend Cuts
- Dividend Cut Impact: Morgan Stanley highlights that while dividend cuts may lead to short-term stock price declines, stocks often rebound after initial reactions, particularly when companies improve their financial positions.
- Healthcare Realty Trust Performance: This real estate investment trust cut its dividend by 23% over the past year, yet its stock has risen 20% in 2026, with a current dividend yield of 4.7%, indicating management's execution is exceeding expectations.
- Dow Inc. Adjustment: After halving its dividend to 35 cents per share last July, Dow's stock has surged 42% in 2026, maintaining a 4.2% dividend yield, with the CEO stating this adjustment provides greater financial flexibility for high-return opportunities.
- Market Analyst Trends: Morgan Stanley's report reveals that despite dividend cuts from companies like LyondellBasell and DuPont, analysts remain optimistic about Dow, with nine analysts rating it as a buy or strong buy.
See More
Edwards Lifesciences Corp. Latest Developments
- Company History and Achievements: Founded in 1960, Edwards Lifesciences made history with the first commercially available artificial heart valve, helping over two million cardiac patients worldwide and achieving a market capitalization of $46 billion, underscoring its significance in the medical device industry.
- Strong Growth Momentum: In Q1 2026, the company's heart-related therapies business posted approximately 42% year-over-year growth, prompting an upward revision of full-year sales growth guidance to 9%-11%, with projected revenues between $6.5 billion and $6.9 billion, reflecting robust market demand.
- Improved Profitability: The adjusted EPS guidance was raised to $2.95-$3.05, with operating margins expected at the high end of the 28%-29% range, indicating ongoing enhancements in profitability that bolster investor confidence.
- Technical and Market Strategy: Edwards' stock consolidated between $75 and $87 over the past six months, and after breaking out, it retraced to the $81 area and rebounded, signaling strong buying interest; the healthy RSI indicates sustained bullish sentiment, making it suitable for momentum investment strategies.
See More
First Pacific Advisors' Q1 2026 Investment Moves
- New Additions: In Q1 2026, First Pacific Advisors added 27 stocks, with Baxter International Inc (BAX) being the largest addition at 6,700,925 shares, representing 1.61% of the portfolio and valued at $112.58 million, indicating strong confidence in the healthcare sector.
- Significant Increases: The firm increased stakes in 22 stocks, notably Liberty Broadband Corp (LBRDK), with an additional 1,973,262 shares, a 73.92% increase impacting the portfolio by 1.42% and valued at $233.52 million, reflecting optimism in the communications industry.
- Complete Exits: First Pacific Advisors fully exited 5 holdings this quarter, including Charter Communications Inc (CHTR), selling 461,525 shares, resulting in a -1.29% impact on the portfolio, indicating a cautious outlook on this stock.
- Position Reductions: The firm reduced positions in 23 stocks, with Kinder Morgan Inc (KMI) seeing a significant reduction of 2,743,789 shares, a 67.31% decrease impacting the portfolio by -1.01%, suggesting a reassessment of the energy sector's prospects.
See More
Baxter (BAX) Q1 2026 Earnings Call Transcript
See More
Baxter Exceeds Expectations in Q1 2026 Financials, Shares Rise
- International Sales Growth: Baxter (BAX) reported $2.7 billion in revenue for Q1 2026, reflecting a ~3% YoY increase that surpassed consensus estimates by $80 million, with international sales contributing $1.3 billion and achieving ~12% YoY growth, indicating strong performance in global markets.
- U.S. Market Decline: Despite robust international results, U.S. sales fell to $1.4 billion, representing a ~4% YoY decline, a trend that persists even after excluding results from the divested Kidney Care business, highlighting challenges in the domestic market.
- Adjusted Earnings Per Share: The company's adjusted EPS stood at $0.36, beating estimates by $0.05, although this reflects a ~35% YoY decline primarily due to unfavorable comparisons to the prior year and rising costs related to tariffs and manufacturing, indicating pressure on cost management.
- Full-Year Outlook Reaffirmed: Baxter reaffirmed its full-year sales growth outlook of 0%-1% and adjusted EPS guidance of $1.85-$2.05, compared to the consensus of 1% growth and $1.91 EPS, demonstrating the company's confidence in its future performance.
See More
MediThinQ and Synovis Sign Global Exclusive Agreement
- Global Distribution Agreement: MediThinQ has entered into an exclusive multi-year distribution agreement with Synovis MCA, a subsidiary of Baxter, to promote its 3D surgical visualization platform SHIYA worldwide; while the terms remain undisclosed, this move is expected to significantly enhance SHIYA's accessibility and acceptance in international markets.
- Technological Transformation: SHIYA combines a high-resolution digital exoscope with the proprietary wearable display SCOPEYE, allowing surgeons to operate without traditional eyepieces, thereby enhancing surgical flexibility and team collaboration, which is crucial for modern surgical practices.
- Clinical Validation and Future Applications: SHIYA has been utilized in over 100 procedures globally, with peer-reviewed studies highlighting its potential in microsurgery, particularly in augmented reality and data-assisted surgical techniques, indicating a fundamental shift in surgical methodologies.
- Market Promotion Strategy: The collaboration with Synovis MCA provides the commercial infrastructure necessary for SHIYA's phased rollout across various countries, ensuring compliance with local regulatory requirements, which will accelerate the global adoption of digital surgical visualization technologies.
See More
Investment Opportunities After Dividend Cuts
- Dividend Cut Impact: Morgan Stanley highlights that while dividend cuts may lead to short-term stock price declines, stocks often rebound after initial reactions, particularly when companies improve their financial positions.
- Healthcare Realty Trust Performance: This real estate investment trust cut its dividend by 23% over the past year, yet its stock has risen 20% in 2026, with a current dividend yield of 4.7%, indicating management's execution is exceeding expectations.
- Dow Inc. Adjustment: After halving its dividend to 35 cents per share last July, Dow's stock has surged 42% in 2026, maintaining a 4.2% dividend yield, with the CEO stating this adjustment provides greater financial flexibility for high-return opportunities.
- Market Analyst Trends: Morgan Stanley's report reveals that despite dividend cuts from companies like LyondellBasell and DuPont, analysts remain optimistic about Dow, with nine analysts rating it as a buy or strong buy.
See More
Edwards Lifesciences Corp. Latest Developments
- Company History and Achievements: Founded in 1960, Edwards Lifesciences made history with the first commercially available artificial heart valve, helping over two million cardiac patients worldwide and achieving a market capitalization of $46 billion, underscoring its significance in the medical device industry.
- Strong Growth Momentum: In Q1 2026, the company's heart-related therapies business posted approximately 42% year-over-year growth, prompting an upward revision of full-year sales growth guidance to 9%-11%, with projected revenues between $6.5 billion and $6.9 billion, reflecting robust market demand.
- Improved Profitability: The adjusted EPS guidance was raised to $2.95-$3.05, with operating margins expected at the high end of the 28%-29% range, indicating ongoing enhancements in profitability that bolster investor confidence.
- Technical and Market Strategy: Edwards' stock consolidated between $75 and $87 over the past six months, and after breaking out, it retraced to the $81 area and rebounded, signaling strong buying interest; the healthy RSI indicates sustained bullish sentiment, making it suitable for momentum investment strategies.
See More
First Pacific Advisors' Q1 2026 Investment Moves
- New Additions: In Q1 2026, First Pacific Advisors added 27 stocks, with Baxter International Inc (BAX) being the largest addition at 6,700,925 shares, representing 1.61% of the portfolio and valued at $112.58 million, indicating strong confidence in the healthcare sector.
- Significant Increases: The firm increased stakes in 22 stocks, notably Liberty Broadband Corp (LBRDK), with an additional 1,973,262 shares, a 73.92% increase impacting the portfolio by 1.42% and valued at $233.52 million, reflecting optimism in the communications industry.
- Complete Exits: First Pacific Advisors fully exited 5 holdings this quarter, including Charter Communications Inc (CHTR), selling 461,525 shares, resulting in a -1.29% impact on the portfolio, indicating a cautious outlook on this stock.
- Position Reductions: The firm reduced positions in 23 stocks, with Kinder Morgan Inc (KMI) seeing a significant reduction of 2,743,789 shares, a 67.31% decrease impacting the portfolio by -1.01%, suggesting a reassessment of the energy sector's prospects.
See More
Baxter (BAX) Q1 2026 Earnings Call Transcript
See More
Baxter Exceeds Expectations in Q1 2026 Financials, Shares Rise
- International Sales Growth: Baxter (BAX) reported $2.7 billion in revenue for Q1 2026, reflecting a ~3% YoY increase that surpassed consensus estimates by $80 million, with international sales contributing $1.3 billion and achieving ~12% YoY growth, indicating strong performance in global markets.
- U.S. Market Decline: Despite robust international results, U.S. sales fell to $1.4 billion, representing a ~4% YoY decline, a trend that persists even after excluding results from the divested Kidney Care business, highlighting challenges in the domestic market.
- Adjusted Earnings Per Share: The company's adjusted EPS stood at $0.36, beating estimates by $0.05, although this reflects a ~35% YoY decline primarily due to unfavorable comparisons to the prior year and rising costs related to tariffs and manufacturing, indicating pressure on cost management.
- Full-Year Outlook Reaffirmed: Baxter reaffirmed its full-year sales growth outlook of 0%-1% and adjusted EPS guidance of $1.85-$2.05, compared to the consensus of 1% growth and $1.91 EPS, demonstrating the company's confidence in its future performance.
See More
